We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
McKesson (MCK - Free Report) closed at $823.01 in the latest trading session, marking a +1.13% move from the prior day. This change outpaced the S&P 500's 0.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.09%, and the technology-dominated Nasdaq saw a decrease of 0.59%.
Heading into today, shares of the prescription drug distributor had lost 3.36% over the past month, lagging the Medical sector's gain of 1.12% and the S&P 500's loss of 0.21%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $9.19, marking a 14.45% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $105.66 billion, up 10.88% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $38.61 per share and a revenue of $408.23 billion, demonstrating changes of +16.82% and +13.7%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.13% lower. Right now, McKesson possesses a Zacks Rank of #3 (Hold).
In terms of valuation, McKesson is presently being traded at a Forward P/E ratio of 21.08. This signifies a premium in comparison to the average Forward P/E of 18.23 for its industry.
Meanwhile, MCK's PEG ratio is currently 1.34. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Dental Supplies was holding an average PEG ratio of 2.35 at yesterday's closing price.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Rises As Market Takes a Dip: Key Facts
McKesson (MCK - Free Report) closed at $823.01 in the latest trading session, marking a +1.13% move from the prior day. This change outpaced the S&P 500's 0.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.09%, and the technology-dominated Nasdaq saw a decrease of 0.59%.
Heading into today, shares of the prescription drug distributor had lost 3.36% over the past month, lagging the Medical sector's gain of 1.12% and the S&P 500's loss of 0.21%.
Investors will be eagerly watching for the performance of McKesson in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $9.19, marking a 14.45% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $105.66 billion, up 10.88% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $38.61 per share and a revenue of $408.23 billion, demonstrating changes of +16.82% and +13.7%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.13% lower. Right now, McKesson possesses a Zacks Rank of #3 (Hold).
In terms of valuation, McKesson is presently being traded at a Forward P/E ratio of 21.08. This signifies a premium in comparison to the average Forward P/E of 18.23 for its industry.
Meanwhile, MCK's PEG ratio is currently 1.34. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Dental Supplies was holding an average PEG ratio of 2.35 at yesterday's closing price.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.